Research programme: liver disorder therapeutics - LISCure Biosciences/Mayo Clinic
Latest Information Update: 28 Feb 2026
At a glance
- Originator LISCure Biosciences; Mayo Clinic
- Class Anti-inflammatories; Hepatoprotectants
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver disorders; Primary sclerosing cholangitis
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for research development in Liver-disorders in South Korea
- 28 Feb 2026 No recent reports of development identified for research development in Liver-disorders in USA
- 28 Feb 2026 No recent reports of development identified for research development in Primary-sclerosing-cholangitis in South Korea